via MedicinePlus.gov
[mks_button size=”medium” title=”Exploration Highlights” style=”rounded” url=”http://” target=”_self” bg_color=”#0000FF” txt_color=”#FFFFFF” icon=”” icon_type=”” nofollow=”0″]
- Researchers disrupt molecule that causes excess mucus in lungs, may prompt new treatments for pulmonary disease.
- Scientists have reversed the damage caused by asthma in mice by targeting specific molecules that cause an overproduction of mucus in the lungs and airways. They hope this leads to new drugs to better treat asthma, COPD, cystic fibrosis and perhaps COVID-19.
- Excess mucus in the lungs can be fatal for asthma patients, but scientists at the University of Colorado Anschutz Medical Campus have broken up those secretions at the molecular level and reversed their often deadly effects.
- The researchers explained how they created an inhaled treatment that disrupted the production of excess mucus by reducing disulfide bonds in mice and opening up their airways. The same treatment had similar impacts on human mucus samples.
- Treatments for asthma like bronchodilators and steroids are rarely effective against mucus. Evans said they hydrate the mucus making it easier to cough up, but fail to treat the problem at the molecular level.
- The researchers tried to shut down this process by breaking up mucin disulfide bonds which contribute to the overproduction of mucus. They treated asthmatic mice with a chemical known as TCEP (tris(2-carboxyethyl)phosphine) which quickly reversed the disease. It also worked on human mucus taken as samples from asthma patients.
- “Loosening the mucus reduces airway inflammation, enhances mucociliary clearance and abolishes airway hyperactivity.”
- Such new compounds might also be used in treating pulmonary fibrosis and even infections like pneumonia or Covid-19 which attacks the lungs and airways.
- “These findings establish grounds for developing treatments to inhibit effects of mucus hypersecretion in asthma,” Evans said. “I believe they have life-saving potential.”
Original Article: NCU Anschutz Scientists Reverse Deadly Impacts of Asthma in Mice
More from: Anschutz Medical Campus on Innovation2
[mks_col]
[mks_one_half]
Go deeper with the LATEST Bing News on:
Asthma
- The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drugon April 13, 2021 at 5:14 am
Roche Snags FDA Approval For Self-Injectable, Prefilled Syringe For Asthma Drug Roche Holding AG (OTC: RHHBY) said the U.S. Food and Drug Administration has approved its supplemental Biologics ...
- Common asthma drug speeds up Covid-19 recovery at home, study findson April 13, 2021 at 5:14 am
Oxford University researchers have found that a cheap asthma drug can help speed up recovery for people at home with Covid-19. Inhaled budesonide, a common corticosteroid used to treat asthma and ...
- Asthma drug shortens recovery time in COVID-19 patients at homeon April 13, 2021 at 4:57 am
Early treatment with an asthma drug budesonide shortens recovery time in COVID-19 patients aged over 50 who are treated at home or in other community settings.
- Scientists identify severe asthma species, show air pollutant as likely contributoron April 13, 2021 at 4:42 am
Asthma afflicts more than 300 million people worldwide. The most severe manifestation, known as non-Th2, or non-atopic childhood asthma, represents the majority of the cases, greater than 85%, ...
- Asthma drug holds hope for COVID-19 treatmenton April 13, 2021 at 2:58 am
A steroid commonly used in asthma inhalers has the potential to prevent severe COVID-19 symptoms. It could treat COVID-19 early on and help to reduce pressure on hospitals. A common asthma medication ...
- Cheap £14 asthma inhaler ‘slashes Covid recovery by three DAYS’, experts discoveron April 12, 2021 at 12:54 pm
A CHEAP asthma drug cuts Covid recovery time by three days, scientists at Oxford University have found. Patients treated with budesonide inhalers got better quicker, were less likely to be ...
- Covid: Asthma drug 'speeds up recovery at home'on April 12, 2021 at 7:23 am
There are also early signs the drug could reduce hospital admissions. At present, there are few options for treating people with Covid who are not in hospital, apart from paracetamol. This ...
- Asthma drug budesonide speeds recovery for at-home COVID-19 patientson April 12, 2021 at 7:00 am
Treating COVID-19 patients at home with a commonly-used inhaled asthma drug called budesonide can speed up their recovery, according to UK trial results on Monday which doctors said could change the ...
- Asthma drug accelerates coronavirus recovery in patients ill at home, study suggestson April 12, 2021 at 7:00 am
An asthma drug has shown promise among coronavirus patients who are ill with the infection at home. Early research suggests the coronavirus is mild in four out of five cases, however, it can trigger a ...
- Asthma drug helps older people cope with Covid at home – studyon April 12, 2021 at 6:04 am
Inhaling budesonide found to shorten recovery for over-65s, and over-50s with underlying conditions Last modified on Mon 12 Apr 2021 10.04 EDT A relatively cheap, inhaled asthma drug helps older ...
[/mks_one_half]
[mks_one_half]
Go deeper with the LATEST Bing News on:
New treatments for pulmonary disease
- Amoeba biology reveals potential treatment target for lung diseaseon April 12, 2021 at 9:00 pm
In a series of experiments that began with amoebas -- single-celled organisms that extend podlike appendages to move around -- Johns Hopkins Medicine scientists say they have identified a genetic ...
- Covid disease damage leading to 'completely new category' of organ transplantson April 12, 2021 at 1:49 pm
"I expect this to be a completely new category of transplant patients." Tens of thousands of patients whose organs were otherwise healthy have developed severe, chronic lung disease after having ...
- New Non–Small Cell Lung Cancer Therapies Coming in 2021on April 12, 2021 at 5:42 am
In the United States, non–small cell lung cancer accounts for 80% to 85% of all lung cancers, with most patients initially diagnosed with advanced or metastatic disease.
- Aneuploidy testing can be key in determining optimal treatment for lung cancer patientson April 11, 2021 at 9:33 pm
Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than ...
- Biodesix Releases New Data at AACR on Proteomic Profiling to Help Guide Physician Treatment Strategies for NSCLC Patientson April 10, 2021 at 9:30 am
Biodesix releases new data at AACR annual meeting on the use of proteomic profiling to help guide physician treatment strategies for NSCLC patients.
- Phase 3 clinical trial tests new treatment for brain metastases from small-cell lung canceron April 8, 2021 at 3:17 pm
A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could ...
- Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosison April 8, 2021 at 1:32 pm
Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that ...
- A new treatment for metastatic lung canceron April 7, 2021 at 9:00 pm
A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could ...
- The Deadly Lung Disease You've Probably Never Heard Ofon April 7, 2021 at 3:59 am
Pulmonary fibrosis (PF ... Approximately 50,000 new cases are diagnosed annually, and as many as 40,000 Americans die from IPF each year. There are many factors that make this disease difficult for ...
- New Paper Shows Bronchoscopic Thermal Vapor Ablation (BTVA) Is Feasible and Well Tolerated in the Treatment of Lung Canceron April 1, 2021 at 4:30 am
In 2018, there were more than two million new lung cancer ... tumor location or disease characteristics. Therefore, most early stage lung cancer patients do not have good treatment options today.
[/mks_one_half]
[/mks_col]
